[{"address1": "3891 Ranchero Drive", "address2": "Suite 150", "city": "Ann Arbor", "state": "MI", "zip": "48108", "country": "United States", "phone": "734 887 3903", "website": "https://www.esperion.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.", "fullTimeEmployees": 240, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sheldon L. Koenig", "age": 57, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1278804, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. JoAnne Micale Foody FACC, M.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 856871, "exercisedValue": 0, "unexercisedValue": 3822}, {"maxAge": 1, "name": "Mr. Eric J. Warren R.Ph.", "age": 51, "title": "Chief Commercial Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 718859, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Halladay M.B.A.", "age": 37, "title": "Chief Financial Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Glenn P. Brame", "age": 65, "title": "Chief Technical Operations Officer", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin O. Looker J.D.", "age": 41, "title": "General Counsel & Corporate Secretary", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 550350, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Tiffany  Aldrich M.B.A.", "title": "Associate Director of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Betty Jean Swartz", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 5, "compensationRisk": 6, "shareHolderRightsRisk": 9, "overallRisk": 6, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.34, "open": 2.33, "dayLow": 2.2803, "dayHigh": 2.505, "regularMarketPreviousClose": 2.34, "regularMarketOpen": 2.33, "regularMarketDayLow": 2.2803, "regularMarketDayHigh": 2.505, "beta": 1.021, "forwardPE": 121.50001, "volume": 6972352, "regularMarketVolume": 6972352, "averageVolume": 8408013, "averageVolume10days": 5367430, "averageDailyVolume10Day": 5367430, "bid": 2.41, "ask": 2.43, "bidSize": 4600, "askSize": 300, "marketCap": 460387808, "fiftyTwoWeekLow": 0.7, "fiftyTwoWeekHigh": 3.4, "priceToSalesTrailing12Months": 2.0039515, "fiftyDayAverage": 2.4298, "twoHundredDayAverage": 2.0864, "currency": "USD", "enterpriseValue": 782650496, "profitMargins": -0.37654, "floatShares": 164174922, "sharesOutstanding": 189460000, "sharesShort": 39417019, "sharesShortPriorMonth": 24887802, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.20799999, "heldPercentInsiders": 0.00519, "heldPercentInstitutions": 0.69123, "shortRatio": 3.93, "shortPercentOfFloat": 0.2086, "impliedSharesOutstanding": 189460000, "bookValue": -1.567, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -86507000, "trailingEps": -0.9, "forwardEps": 0.02, "pegRatio": 13.85, "enterpriseToRevenue": 3.407, "enterpriseToEbitda": -22.643, "52WeekChange": 0.58823526, "SandP52WeekChange": 0.17829525, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ESPR", "underlyingSymbol": "ESPR", "shortName": "Esperion Therapeutics, Inc.", "longName": "Esperion Therapeutics, Inc.", "firstTradeDateEpochUtc": 1372253400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "00314c6d-38c1-3c8e-a318-bd51d9ba1c8c", "messageBoardId": "finmb_28236", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.43, "targetHighPrice": 16.0, "targetLowPrice": 2.55, "targetMeanPrice": 7.36, "targetMedianPrice": 8.0, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 226608992, "totalCashPerShare": 1.196, "ebitda": -34565000, "totalDebt": 548870976, "quickRatio": 1.709, "currentRatio": 2.222, "totalRevenue": 229740000, "revenuePerShare": 1.826, "returnOnAssets": -0.06939, "freeCashflow": -45357752, "operatingCashflow": -27303000, "revenueGrowth": 4.661, "grossMargins": 0.52199, "ebitdaMargins": -0.15045, "operatingMargins": 0.5247, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-26"}]